Core Viewpoint - The article discusses the recent results of the "3+N" alliance procurement project for hemostatic materials in the Beijing-Tianjin-Hebei region, highlighting the shift in medical device procurement policies towards higher value products and the opportunities for domestic companies with innovative technologies [1][3]. Group 1: Procurement Policy Changes - The volume-based procurement policy is significantly altering the landscape of the medical device market, particularly in the hemostatic materials sector, where there is a growing demand for efficient, safe, and user-friendly innovative products [2][3]. - The recent procurement project indicates a trend towards higher value products, moving away from a focus solely on low-cost consumables to include clinical value and innovation in the evaluation criteria [3][5]. Group 2: Successful Bids and Innovations - The successful bid of Maipu Medical's Ji Su Ting® absorbable regenerated oxidized cellulose hemostatic product is attributed to its unique material properties and clinical applicability [6][9]. - The product is designed for various surgical procedures, demonstrating superior performance in promoting platelet aggregation and reducing surgical time and complication risks compared to traditional materials [8][9]. Group 3: Industry Trends and Future Outlook - The selection of Ji Su Ting® reflects the broader trend of domestic high-end hemostatic materials gaining traction in the market, as domestic companies enhance their R&D capabilities and clinical trial data [9][10]. - The volume-based procurement policy provides a pathway for innovative products to enter hospitals more rapidly, allowing for the accumulation of clinical usage data and feedback for further optimization [9][10]. - Maipu Medical plans to continue investing in R&D to optimize existing product performance and expand its product line to meet diverse clinical needs [9][10].